Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. - Wikidata - awgldk - TriplyDB

Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2.

Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2.

http://www.wikidata.org/entity/Q34779629

about

Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging Nanoparticles for brain drug delivery Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Development of targeted therapies in treatment of glioblastoma Brain tumor-targeted drug delivery strategies Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?The potential of polymeric micelles in the context of glioblastoma therapy.Progress toward in vivo use of siRNAs-II Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements Novel lactoferrin-conjugated amphiphilic poly(aminoethyl ethylene phosphate)/poly(L-lactide) copolymer nanobubbles for tumor-targeting ultrasonic imaging.Bionanotechnology and the future of glioma.Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties Nanoprobes visualizing gliomas by crossing the blood brain tumor barrier.Progress on the diagnosis and evaluation of brain tumors.Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents.Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease Agile delivery of protein therapeutics to CNS Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.Glioma-targeting micelles for optical/magnetic resonance dual-mode imaging.Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1.Glioblastoma multiforme: novel therapeutic approaches Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review.Multifunctional upconversion nanoparticles for targeted dual-modal imaging in rat glioma xenograft.Phage display as a tool to discover blood-brain barrier (BBB)-shuttle peptides: panning against a human BBB cellular model.Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.A novel synergetic targeting strategy for glioma therapy employing borneol combination with angiopep-2-modified, DOX-loaded PAMAM dendrimer.Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells.Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivo Nanotechnology-novel therapeutics for CNS disorders Transport characteristics of a novel peptide platform for CNS therapeutics.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Differential receptor-mediated drug targeting to the diseased brain.

P2860

Q21223671-0B18C514-5E36-427E-B19B-82366331011D Q21285117-9EE11878-3803-4BB3-AF4A-6B718DBB6867 Q24621947-B8EB7431-28E9-47C3-8A29-9B54B591E4F7 Q26778701-518D7FA6-FBF4-42D8-B07D-C41CDD5D7B3A Q26778787-CC418180-1716-4C95-A9DB-BDB40DC6D672 Q26829741-9C087163-B4A2-4065-A768-982B6E94138C Q27341864-9AB2448B-F1E2-4E23-96BA-A4F30BAD6205 Q27690256-6C6B9078-42CD-48D0-B3D3-A3D50618AA04 Q27693205-F1A48F8B-27DC-4A80-A55F-9F5707D0141A Q28255877-22F0F99B-B854-4240-B542-2A64612ACEC8 Q28729033-972E7506-AC49-4B18-B451-03C03D13EB28 Q30393215-200BC076-334D-4A4A-985E-B799A1562D3F Q30402602-8B8A654C-21B3-4D6D-8D56-7F4828A8AEE5 Q30417964-F93E6DBF-4459-4E69-A9E9-A2F489C7590F Q30572687-49ACCFF6-B2FC-417B-80C0-602DCB95F60D Q30672749-C772141E-AB18-4708-9A9E-C94B8DEC3722 Q30714285-20B65F14-4BC8-4D64-AB0F-DEEA7711C2A1 Q33646512-A863EC06-2CA1-4A81-BD01-573CD66DA359 Q33786343-4378F863-5562-4188-B0BA-590DBF8B2BA5 Q33895840-EB36807F-46AF-480D-8565-DC0D81C9A2BA Q34079647-E27D822A-D408-400A-99A9-F54719D5931D Q34274025-6B1238ED-5E7A-45A3-938C-49C424CFE3D1 Q34539778-59D29553-0F79-4CC2-ABA5-45AC3D7A48BE Q35168731-374DC5C0-2B4C-4076-8818-A45B7C95DEFA Q35559895-6AC2E5CC-5974-4A49-A9CD-24D31D745699 Q35623290-47319BC4-5A99-4847-A950-3DEDEF2993F6 Q35825491-F6E25C7E-F155-43D4-AA14-C117C52DDAC7 Q35997103-14E24665-36A4-49D2-8824-2574E85B4C2F Q36070306-0010F26A-4ECF-40D9-893A-1A02296ABF9B Q36093633-744D25AE-08CE-4A23-B1A0-30C045BC4E7D Q36205039-B5D2394C-7582-4A9D-8299-7692D85317E9 Q36330297-ED16E2AC-D7E2-4C3A-8E01-7A12C178BEE5 Q36333938-D9E42B71-33CE-41FE-A0F5-B40231A7904D Q36411071-D10CF24B-BDC4-433B-8707-E72C8F8B7F3E Q36575704-E846C328-83BA-4B1B-A64D-B41013E2D18F Q36652635-7020B954-90F6-4D48-8B80-DC9514FC8595 Q37173643-61E61A0C-D636-4F0F-B449-35104F149D9F Q37294333-9B115DF2-B463-49F0-BC2B-562AD6A46030 Q37312010-85206A45-4AC7-43D4-9F4F-4E2493906493 Q37425213-CEEB3152-F97E-42A8-9292-236F6374BDD1

P2860

Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2.

http://www.wikidata.org/entity/Q34779629

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Involvement of the low-density ...... in delivery vector angiopep-2.

@ast

Involvement of the low-density ...... in delivery vector angiopep-2.

@en

Involvement of the low-density ...... in delivery vector angiopep-2.

@nl

type

label

Involvement of the low-density ...... in delivery vector angiopep-2.

@ast

Involvement of the low-density ...... in delivery vector angiopep-2.

@en

Involvement of the low-density ...... in delivery vector angiopep-2.

@nl

prefLabel

Involvement of the low-density ...... in delivery vector angiopep-2.

@ast

Involvement of the low-density ...... in delivery vector angiopep-2.

@en

Involvement of the low-density ...... in delivery vector angiopep-2.

@nl

P1433

Q34779629-58BF04B5-5F74-4AEC-A570-78997CDEA536

P1476

Q34779629-AD92C2AC-76B6-47EC-9DD8-8D50610E31FA

P2093

Q34779629-2ACFFED5-5741-451F-A32A-95E19DA6EF4B

Q34779629-7A0FBCEC-F57C-4328-BF59-315A64948D6C

Q34779629-8B72EB3B-3066-4E22-B9FF-AD6325EDE0BE

Q34779629-92C5DE7B-A755-4802-BB58-60BCC15260A4

Q34779629-95A12FEF-7BCB-4565-A4F1-ECAD7E409CF1

Q34779629-9665AF5F-2362-4113-8B79-5D98613BCB96

Q34779629-A19226A6-5FA0-40FC-8F17-943BBAF61067

Q34779629-BBA6E7C4-8DAA-4BD3-B67B-F23D6EA506EC

Q34779629-DF43BC69-E615-40BB-B9F2-4EDDEFE7E9E4

P304

Q34779629-41A0AB47-A9A6-4CF9-88EA-67F1DE056C76

P31

Q34779629-0E3BDA5A-55A2-42AA-8EF3-3BA1316AA867

P356

Q34779629-91006C11-743B-47BB-8775-87611C3EAF5D

P407

Q34779629-427AA457-ED13-4B51-9DBD-B7FADBB6A374

P433

Q34779629-6B01EEF0-7F9A-4E06-A86D-2A9BD14CE04C

P478

Q34779629-5B2C4F3F-B89A-4711-943B-C22EEC50BB72

P577

Q34779629-FBD06D02-F49E-44AD-857E-148A730E0DE2

P5875

Q34779629-EEC1370D-C880-4ED8-AC07-07A2124E8A80

P698

Q34779629-F5B718A0-5203-4496-A964-1A3634FBD80B

P921

Q34779629-5C8F4840-391C-4358-96F8-AEE06444F2F6

P356

J.1471-4159.2008.05492.X

P1433

Journal of Neurochemistry

P1476

Involvement of the low-density ...... in delivery vector angiopep-2.

@en

P2093

Anthony Régina

http://www.w3.org/2001/XMLSchema#string

Christian Ché

http://www.w3.org/2001/XMLSchema#string

Jean-Christophe Currie

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Castaigne

http://www.w3.org/2001/XMLSchema#string

Michel Demeule

http://www.w3.org/2001/XMLSchema#string

Reinhard Gabathuler

http://www.w3.org/2001/XMLSchema#string

Richard Béliveau

http://www.w3.org/2001/XMLSchema#string

Tran Nguyen

http://www.w3.org/2001/XMLSchema#string

Yanick Bertrand

http://www.w3.org/2001/XMLSchema#string

P304

1534-1544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1471-4159.2008.05492.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5360142

http://www.w3.org/2001/XMLSchema#string

P698

18489712

http://www.w3.org/2001/XMLSchema#string

P921